Pharma and Healthcare Insight

Pharma & Healthcare Insight brings you analysis of regional trends, regulatory changes, projects and investments plus competitive intelligence on the growth strategies of leading companies in the sector

See Prices or Subscribe

Key stories from this month's issue...

Industry Trend Analysis - High Inflation Masks Drugmaker Challenges - OCT 2017

Americas September 2017 / Argentina / Industry

Argentina will remain a key market in the Latin America region; however, the outlook will be masked by the implications of the high inflation environment. Medicine accessibility will be reduced and the potential for further price controls may repress sales growth. While economic reforms will reduce these issues, access to innovative medicines will remain supressed due to regulatory issues, compounded by changes to reimbursement.


Industry Trend Analysis - Challenging Business Environment To Impact Pharmaceutical Market Growth - OCT 2017

Asia September 2017 / Japan / Industry

Japan will remain an important market for innovative drugmakers - the large market size, considerable purchasing power and the strength of the regulatory environment all contribute to creating revenue-earning opportunities for drugmakers. However, an increasingly tough pricing environment and a push towards the consumption of generic medicines will impact the commercial opportunities for multinational drugmakers in in the country.


Industry Trend Analysis - Reimbursement Changes Increase Pricing Pressures - OCT 2017

Emerging Europe September 2017 / Lithuania / Industry

Drugmaker opportunities in Lithuania will face challenges from the increasingly aggressive pricing regime. Reimbursement changes in 2017 have led to downward pressure on prices, exemplified by the new mechanism imposed in July 2017. While these changes and additional proposals will likely boost access to pharmaceuticals, the potential for growth remains severely restricted.


Industry Trend Analysis - Algerian Insulin Agreement Highlights Biocon's Biologic Ambitions - OCT 2017

Middle East & Africa September 2017 / Algeria / Industry

This collaboration complements Biocon's efforts to commercialise its biologic and biosimilar products in less well-regulated markets, but enhances Abdi Ibrahim's expansion aims also. Biocon's Biologic segment is still a small part of its business, but has grown quickly over the last few years. Launching its insulin product in Algeria will further boost sales, but its partnership with Mylan will ultimately mean the more valuable US and European biosimilar markets will be in reach imminently.


Industry Trend Analysis - Novartis Will Take Advantage Of Ibrance's Slow Movement In EU - OCT 2017

Western Europe September 2017 / Europe / Industry

The approval of Kisqali in the EU will aid Novartis' ambitious growth plans for this drug. It will lag behind the market leader, Pfizer's Ibrance, which has capitalised on first-to-market status. Novartis has an opening to gain market share in Europe, which will be supported by its flexible pricing strategies as Pfizer struggles to gain traction with Ibrance in this region.